Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Feb 23;19(2):e0299197.
doi: 10.1371/journal.pone.0299197. eCollection 2024.

Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial

Bruno Martins Tomazini  1   2   3 , Lucas Tramujas  1 , Fernando Azevedo Medrado Junior  1 , Samara Pinheiro do Carmo Gomes  1 , Karina Leal Negrelli  1 , Gabriela Souza Murinize  1 , Renato Hideo Nakagawa Santos  1 , Bruna Martins Pereira Vianna  1 , Bruna Fornazieri Piotto  1 , Thabata Silva Veiga  1 , Bianca Rodrigues do Santos  1 , Ana Clara Peneluppi Horak  1 , Olivia Mora Cavalcante Lemos  4 , Marcela de Almeida Lopes  1 , Beatriz Baptista Olicheski  4 , Diego Lurentt Campones  4 , Luiz Angelo Alencar Peixoto  4 , Aline Dos Anjos Chaves Basilio  4 , Otavio Celso Eluf Gebara  5 , Ana Tarina Alvarez Lopes  5 , Humberto Saconato  5 , Nanci Valeis  1 , Tamiris Abait Miranda  1 , Ligia Nasi Laranjeira  1 , Eliana Vieira Santucci  1 , Aaron Foster Carlin  6 , Jeffrey David Esko  7 , Phillip Leo Stephan Marie Gordts  8 , Sotirios Tsimikas  9 , Alexandre Biasi Cavalcanti  1   2
Affiliations
Clinical Trial

Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial

Bruno Martins Tomazini et al. PLoS One. .

Abstract

Background: Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent in vitro activity against SARS-CoV-2 virus. The safety and efficacy of halofuginone in Covid-19 patients has not been studied.

Methods: We conducted a phase II, randomized, double-blind, placebo-controlled, dose ranging, safety and tolerability trial of halofuginone in symptomatic (≤ 7 days), mostly vaccinated, non-hospitalized adults with mild to moderate Covid-19. Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. The primary outcome was the decay rate of the SARS-CoV-2 viral load logarithmic curve within 10 days after randomization.

Results: From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log10 within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). There was no difference on bleeding episodes or serious adverse events at 28 days.

Conclusions: Among non-hospitalized adults with mild to moderate Covid-19 halofuginone treatment was safe and well tolerated but did not decrease SARS-CoV-2 viral load decay rate within 10 days.

PubMed Disclaimer

Conflict of interest statement

S.T is a co-inventor and receives royalties from patents owned by University of California San Diego (UCSD) and is a co-founder and has an equity interest in Oxitope, LLC and its affiliates, Kleanthi Diagnostics, LLC and Covicept Therapeutics, Inc and has a dual appointment at UCSD and Ionis Pharmaceuticals; A.F.C has received contract payments from Nurix Therapeutics, Inc. and has options in Covicept Therapeutics; J.D.E is a cofounder, consultant and shareholder in Covicept Therapeutics (San Diego, CA) and TEGA Therapeutics (La Jolla, CA); P.L.S.M.G. is a cofounder, consultant and shareholder in Covicept Therapeutics (San Diego, CA). All remaining authors: No conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials, although some restrictions might apply as stated in the submission.

Figures

Fig 1
Fig 1. Flow of patients in Halos trial.
Fig 2
Fig 2. Symptoms free-days up to day 10.
Fig 3
Fig 3. Mean SARS-CoV-2 viral load log 10 between groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al.. Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine. 2022;386(18):1721–31. doi: 10.1056/NEJMoa2115869 - DOI - PMC - PubMed
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al.. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine. 2021;386(6):509–20. doi: 10.1056/NEJMoa2116044 - DOI - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al.. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022;386(15):1397–408. doi: 10.1056/NEJMoa2118542 - DOI - PMC - PubMed
    1. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al.. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine. 2021;386(4):305–15. doi: 10.1056/NEJMoa2116846 - DOI - PMC - PubMed
    1. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine. 2020;383(21):2041–52. doi: 10.1056/NEJMoa2019014 - DOI - PMC - PubMed

Publication types